Weight Gain: A Possible Side Effect of All Antiretrovirals

Lucia Taramasso, Elena Ricci, Barbara Menzaghi, Giancarlo Orofino, Simone Passerini, Giordano Madeddu, Canio Vito Martinelli, Giuseppe Vittorio De Socio, Nicola Squillace, Stefano Rusconi, Paolo Bonfanti, Antonio Di Biagio, CISAI Study Group, T Quirino, P Bonfanti, E Ricci, C Bellacosa, P Maggi, L Calza, C Abeli, B Menzaghi, B M Celesia, C Grosso, A Stagno, F Vichi, F Mazzotta, C Martinelli, G Penco, G Cassola, A Di Biagio, L Taramasso, L A Nicolini, C Dentone, C Molteni, L Palvarini, A Scalzini, L Carenzi, G Rizzardini, L Valsecchi, L Cordier, S Rusconi, V Colombo, M Galli, M Franzetti, G V De Socio, E Mazzotta, G Parruti, G Madeddu, P Bagella, M S Mura, R Libertone, A Antinori, S Di Giambenedetto, G Orofino, M Guastavigna, P Caramell, Lucia Taramasso, Elena Ricci, Barbara Menzaghi, Giancarlo Orofino, Simone Passerini, Giordano Madeddu, Canio Vito Martinelli, Giuseppe Vittorio De Socio, Nicola Squillace, Stefano Rusconi, Paolo Bonfanti, Antonio Di Biagio, CISAI Study Group, T Quirino, P Bonfanti, E Ricci, C Bellacosa, P Maggi, L Calza, C Abeli, B Menzaghi, B M Celesia, C Grosso, A Stagno, F Vichi, F Mazzotta, C Martinelli, G Penco, G Cassola, A Di Biagio, L Taramasso, L A Nicolini, C Dentone, C Molteni, L Palvarini, A Scalzini, L Carenzi, G Rizzardini, L Valsecchi, L Cordier, S Rusconi, V Colombo, M Galli, M Franzetti, G V De Socio, E Mazzotta, G Parruti, G Madeddu, P Bagella, M S Mura, R Libertone, A Antinori, S Di Giambenedetto, G Orofino, M Guastavigna, P Caramell

Abstract

Weight gain and body mass index (BMI) increase are central issues in patients living with HIV who need to minimize the risk of metabolic disease. Information collected through the SCOLTA cohort revealed significant 1-year BMI increase in patients treated with dolutegravir (P = .004), raltegravir (P = .0004), elvitegravir (P = .004), darunavir (P = .0006), and rilpivirine (P = .029). BMI gain correlated with low baseline BMI (P = .002) and older age (P = .0007) in Centers for Disease Control and Prevention stages A/B, with lower BMI (P = .005) and CD4+ T-cell count (P = .007) at enrollment in stage C.

Keywords: ART; BMI; INSTI; cardiovascular risk; darunavir; rilpivirine; weight.

References

    1. Armah KA, Chang CC, Baker JV et al. ; Veterans Aging Cohort Study (VACS) Project Team Prehypertension, hypertension, and the risk of acute myocardial infarction in HIV-infected and -uninfected veterans. Clin Infect Dis 2014; 58:121–9.
    1. European AIDS Clinical Society (EACS). EACS Guidelines. 2017. Available at: . Accessed 10 August 2017.
    1. Womack JA, Chang CC, So-Armah KA et al. . HIV infection and cardiovascular disease in women. J Am Heart Assoc 2014; 3:e001035.
    1. Freiberg MS, Chang CC, Kuller LH et al. . HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173:614–22.
    1. Butt AA, McGinnis K, Rodriguez-Barradas MC et al. ; Veterans Aging Cohort Study HIV infection and the risk of diabetes mellitus. AIDS 2009; 23:1227–34.
    1. Capeau J, Bouteloup V, Katlama C et al. ; ANRS CO8 APROCO-COPILOTE Cohort Study Group Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 2012; 26:303–14.
    1. Friis-Møller N, Sabin CA, Weber R et al. ; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993–2003.
    1. Herrin M, Tate JP, Akgün KM et al. . Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals. J Acquir Immune Defic Syndr 2016; 73:228–36.
    1. Norwood J, Koethe JR, Turner M et al. . Weight gain in persons with HIV switched from Efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr 2017; doi: 10.1097/QAI.0000000000001525.
    1. Menard A, Meddeb L, Tissot-Dupont H et al. . Dolutegravir and weight gain: an unexpected bothering side effect? AIDS 2017; 31:1499–500.
    1. McComsey GA, Moser C, Currier J et al. . Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. Clin Infect Dis 2016; 62:853–62.
    1. Bonfanti P, Martinelli C, Ricci E et al. ; CISAI Group (Italian Coordinators for the Study of Allergies HIV Infection) An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir. J Acquir Immune Defic Syndr 2005; 39:317–20.
    1. Stenholm S, Vahtera J, Kawachi I et al. . Patterns of weight gain in middle-aged and older US adults, 1992–2010. Epidemiology 2015; 26:165–8.
    1. European Commission. Eurostat Statistic Explained. 2014. Available at: . Accessed 23 October 2017.
    1. Koethe JR, Jenkins CA, Lau B et al. ; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retroviruses 2016; 32:50–8.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する